Immunomodulatory therapy in multiple sclerosis and breast cancer risk: A case report and literature review

Clinical Breast Cancer

Volumn 8, Issue 5, 2008, Pages 449-452

  Amaria, Rodabe ^a   Corboy, John ^a   Finlayson, Christina ^a   Robinson, William ^a   Borges, Virginia ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Glatiramer acetate; Interferons; Mitoxantrone; Natalizumab; Regulatory T cells

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GLATIRAMER; IMMUNOMODULATING AGENT; PACLITAXEL; STEROID; TRASTUZUMAB; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; PEPTIDE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AORTIC VALVE ENDOCARDITIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER RADIOTHERAPY; CANCER RISK; CASE REPORT; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PHENOTYPE; PHYSICAL EXAMINATION; PROGNOSIS; REGULATORY T LYMPHOCYTE; SUPERIOR CAVA VEIN SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR;

ADJUVANTS, IMMUNOLOGIC; BREAST NEOPLASMS; FEMALE; HUMANS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; RISK FACTORS;

EID: 58149232644     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.055     Document Type: Article

References (33)

1. V. Compston DA, ed. McAlpine's Multiples Sclerosis. 3rd ed. New York: Churchill Livingstone; 1998.
2. Weinshenker BG. The epidemiology of multiple sclerosis. Neurol Clin 1996; 14:291-308.
3. Bray P, Bloomer L, Salmon V, et al. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 1983; 40:406-8.
4. Myhr K, Risse T, Barrett-Connor E, et al. Altered antibody pattern to Epstein-Barr virus but not other herpes viruses in multiple sclerosis: a population based case-control study from western Norway. J Neurol Neurosurg Psych 1998; 64:539-42.
5. Munch M, Hvas J, Christensen T, et al. The implications of Epstein-Barr virus in multiple sclerosis-a review. Acta Neurol Scand Suppl 1997; 97:171-4.
6. Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 2005; 24:211-26.
7. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199:971-9.
8. Kriegel MA, Lohmann T, Gabler C, et al. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 2004; 199:1285-91.
9. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-85.
10. Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-9.
11. The INFB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45:1277-85.
12. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1996; 39:285-94.
13. PRISMS (Prevention of Relapse and Disability by Interferon Î-1b Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-504.
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268-76.
15. Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 2007; 6:469-75.
16. Jee Y, Piao WH, Liu R, et al. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 2007; 125:34-42.
17. Fox, EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006; 28:461-74.
18. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15-23.
19. Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Eng J Med 2005; 353:432-3.
20. Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 2007l; 13:182-7.
21. Surveillance Epidemiology and End Results Database. Breast cancer, 2007. Available at: http://seer.cancer.gov/statfacts/html/breast. html
22. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-61.
23. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80.
24. Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 2008; 8:57.
25. Percy AK, Nobrega FT, Okazaki H, et al. Multiple sclerosis in Rochester, Minn. A 60 year appraisal. Arch Neurol 1971; 25:105-11.
26. Palo J, Duchesne J, Wikstrom J. Malignant disease among patients with multiple sclerosis. J Neurol 1977; 216:217-22.
27. Allen IV, Millar JH, Hutchinson MJ. General disease in 120 necropsy-proven cases of multiple sclerosis. Neruopathol Appl Neurobiol 1978; 4:279-84.
28. Sadovnick AD, Eisen K, Ebers GC, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41:1193-6.
29. Moller H, Kneller RW, Boice JD, et al. Cancer incidence following hospitalization for multiple sclerosis in Denmark. Act Neurol Scand 1991; 84:214-20.
30. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998; 65:56-9.
31. Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006; 118:979-84.
32. Midgard R, Glattr E, Gronning M, et al. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 1996; 93:411-5.
33. Achiron A, Barak Y, Gail M, et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Can Res Treat 2005; 89:265-70.